Hello, we are interested in understanding better how sales force for leading pharma is changing in the face of personalised medicine revolution.
Are reps co-promoting diagnostic testing?
Who is training them in pm?
How are they targeting docs?
Interested in any large/mid size pharma with pm therapies with clear diagnostic strategy on market or in the pipeline.
Thanks and have a good day.+6 Other Responses
Pharmaceutical Secondary Market Research
I am currently looking for an expert from pharmaceutical/healthcare industry (preferably ex-employees of major pharma companies) who knows in and out about secondary market research category (ims health data) in terms of developing strategy, types of data, strengths, weakness, threats and case examples for data purchase?
+8 Other Responses
Pharmaceutical Contract Sales
Project : study on pharmaceutical companies sourcing sales reps from contract sales organizations
industry: pharmaceuticals, contract sales
scope: australia, belgium, netherlands, saudi arabia, puerto rico, venezuela.
We are doing a project on procuring sales force from contract sales organizations in various markets. Request expert guidance in understanding the procurement best practices followed by leading pharmaceutical companies while sourcing contract sales reps from contract sales organizations+9 Other Responses
Pharmaceutical Distribution Rates
I am currently working for a pharmaceutical/healthcare client based in the us. My client is looking for benchmark discounted rates offered for distribution of their products in the us. Below are the deliverable details for which i am looking for benchmarked/industry average discounted rates in the us
1) volume ranges per day
ii) 50,000- 100,000
2) discounted rates offered for the above-mentioned volume ranges based on the type of supplier mentioned below
i) global supplier (international suppliers operating across the globe) - how much % of discount is offered for the above-mentioned volume ranges
ii) local supplier (suppliers operating within the country) - how much % of discount is offered for the above-mentioned volume ranges
iii) regional supplier (suppliers operating in more than 1 country) - how much % of discount is offered for the above-mentioned volume ranges
kindly revert back if the above is feasible
anjana +undefined Other Responses
Healthcare Promotional Items
Title: promotional items
one of our leading pharmaceutical clients is interested to learn about the promotional items offered to the healthcare professionals and pharmacists. Expert insights are needed on the industry overview, procurement best practices and slas, pricing models and cost structure in the following countries: australia, austria, belgium, denmark, finland, france, germany, greece, ireland, italy, netherlands, new zealand, norway, poland, portugal, spain, sweden, switzerland, turkey, united kingdom+15 Other Responses
Pharmaceuticals, Vaccines And Consumer Products Distribution
"pharmaceuticals, vaccines and consumer products-distribution sourcing"
1. Sourcing best practice
a. What are the sourcing approaches followed by global organizations when dealing with distributors/wholesalers across pharmaceutical, consumer and vaccine business? (centralized/decentralized)
2. Engagement best practice
a. What is the best practice followed by companies when engaging for distribution services across pharmaceutical, consumer and vaccine business?
I. Is it engaging with a distributor or wholesaler?
· global/regional/local distributors?
· single or multiple distributors?
3. Feasibility of integrating the distribution model for pharmaceuticals, consumer and vaccine business
a. How do companies with multiple business units such as pharmaceutical, consumer and vaccine business manage this category?
I. Is there a chance of integrating the distribution of these three business units with single set of distributors?
Ii. What are the advantages and disadvantages of following the integration approach?+9 Other Responses
Creative Services For Pharmaceuticals
Creative and digital agency for pharmaceuticals
- what is the best sourcing model for creative and digital services for pharmaceutical companies?
- what is the sourcing approach followed typically by leading pharmaceutical companies? (full-service model or specialized agency model)?
- do large pharma/vaccines companies bundle digital and creative work to single agencies?
- what is the most optimal pricing model while engaging with digital and creative agencies to assure transparency and control of costs?
- is fixed price or performance based pricing or any other?
- i would like to understand if fixed price model is most effective pricing model to control costs while engaging with creative and digital agencies.+10 Other Responses
Vaccines, consumer healthcare and pharma :
market size, growth rate and growth forecast for
1) consumer healthcare categories :
. Oral healthcare
regions in focus:
south east asia
new zealand+7 Other Responses
Pharmaceuticals Reverse Logistics
We are looking to do multiple paid phone consultations with experts from pharmaceutical returns providers with recent experience not more than 2 years ago. We would like to get a better understanding of learning about the operational capability and capacity of different niche market players to handle returns of controlled substances prescriptions on behalf of retailers and manufacturers.
This is a 1-hour paid phone consult. Please consider summarizing your relevant experience with short answers to the questions below:
1. Can you discuss how pharma companies generate data for overstocked, expired and in-dated pharmaceutical products?
2. Can you share the major challenges in handling returns of controlled substances prescriptions on behalf of retailers and manufacturers?
3. Can share your insight on the operational capability and capacity of different niche market players?+undefined Other Responses
International Pharmaceutical Reimbursement
on one for our projects on neuropathic pain and schizophrenia/major depressive disorder we are looking for reimbursement experts and regulator experts who have knowledge and worked in/on emerging markets (china, india, taiwan, korea, mexico, turkey, russia, brazil, australia, canada).
We need one expert for each of the countries; china, india, taiwan, korea, mexico, turkey, russia, brazil, australia, canada.
A few requirements of such experts are listed below, according relevant experts may please forward their responses asap.
§ knowledgeable about drug approval process/guidelines (particularly for indications of interest)in the country
§ knowledgeable about regulations for conducting clinical trials in the country
§ knowledgeable about similarities & differences in regulations/guidelines their specified country vs. Us/eu (especially related to branded vs. Generic medications)
§ knowledgeable about national reimbursement policies/procedure followed in the country (particularly for drugs used in indications of interest)
§ knowledgeable about pharmaceutical pricing policies in the country
§ knowledgeable about access to healthcare in the country
§ knowledgeable about reimbursement procedure/ formulary inclusion process (particularly for indications of interest)for drugs in the country
note: regulatory expert/reimbursement expert can be from public organizations or private organizations or independent consultants and may not be located in any part of the world.
Interested members can reply to this post asap and communicate with me.
Thanks and regards+24 Other Responses
Pharmaceutical Market Access
Director, market access opportunity onsite in california, usa.
the director market access will be a strategic business leader responsible for developing a comprehensive reimbursement, pricing, contracting, and distribution strategy for heplisav-b in the us to support launch in 2016. In addition, the director market access will provide guidance and insights to support commercial planning for pipeline products.
build out the infrastructure for the pricing, contracting, distribution and payer team.
Develop and execute market access strategies focused on reimbursement, pricing, contracting, and commercial distribution related to heplisav-b and future pipeline products across multiple disease states.
Apply deep understanding of national and local reimbursement trends and policies, payer coding and billing, and newly forming health care delivery models to develop managed market strategies.
Lead development and execution of contracting strategy for heplisav-b and future pipeline products.
Lead all aspects of payer coverage to support appropriate reimbursement of heplisav-b.
Develop dossier and other materials as needed to support payer acceptance.
Responsible for all distributor and gpo accounts, including contract negotiations, ongoing relationship management, and day to day operational activities.
Execute retail pharmacy channel distribution strategy in conjunction with product marketing.
Manage 3pl activities related to interactions with distribution network.
Work with commercial analytics to develop metrics/dashboards to assess performance of pricing and contracting strategy.
at least 10 years of experience in the biotech or pharmaceutical industry;
at least 5 years’ experience in a market access/reimbursement/key account position with proven success
ba/bs with relevant experience;
understanding of billing and coding with experience in the implementation of pricing and contracting strategy;
comprehensive knowledge of us healthcare reimbursement system in both commercial and government payer;
demonstrated experience with specialty pharmacy and wholesalers.+6 Other Responses
Hi zintro expert,
the zintro blog needs you!
*a brief answer to the prompt about 1-2 paragraphs including your full name
*participation is voluntary no payment will be involved
*if chosen, you will be named in the post and we'll include a link to your zintro profile which will generate more visitors for you
topic and prompt
global pharmaceuticals companies have seen an improvement in their drugs pipelines but the industry is facing a fresh challenge as the first generation of blockbuster biological drugs begins to face competition. Bristol-myers squibb and eli lilly have the strongest late-stage pipelines relative to existing revenues, while astrazeneca has shown the greatest improvement over the past two years, says a report by credit rating agency moody’s. However, those same three companies also face the greatest exposure to patent expiries over the next three years, highlighting the perennial battle faced by drugmakers to develop new medicines as old ones lose market exclusivity.
What are your thoughts?
Getting your name and expert opinion published on our blog is a great marketing opportunity. If interested, please send a response to the prompt via znotes within 1-2 days. Don't forget to include your full name.
If you have any questions, please let us know.
the zintro blog team
wondering what the post would look like? Here is a sample:
/>+4 Other Responses